PARP1 and ovarian cancer: Also in late line ovarian cancer patients who progressed on PARP inhibitor treatment,195 adavosertib monotherapy induced an ORR of 23% (90% CI, 12%-38%), a clinical benefit rate (CBR) of 63% (90% CI, 48%-76%), and mPFS of 5.5 (90% CI, 3.9–6.9) months (Table 6).